Zantac Cancer Prompts FDA To Seek Answers

FDA database queries find that ranitidine has a higher likelihood of causing cancer than heartburn drugs that do not contain NDMA

Wednesday, January 20, 2021 - Post-market adverse event reporting is the cornerstone of the Food and Drug Administration (FDA) 501 fast track drug approval system. A drug company can get FDA-approval in weeks, not months or years if they can show a panel of scientific experts at the FDA that the drug is substantially similar to one that is already on the market. Untested drugs are rushed to market rather than bog it down with human testing. Thus, the FDA relies on complaints made to them by physicians and patients about adverse side-effects to decide whether the drug is safe. In theory, the FDA queries their database and selects complaints that meet their criteria. Zantac Cancer lawsuits are represented by top national attorneys with vast experience handling litigations against big corporations and pharmaceutical companies and offer a free consultation with no obligation to file.

Although the 501 k fast track has allowed products to reach the market efficiently and saved countless lives, it is not without its shortcomings. Relying on adverse event reports makes patients human guinea pigs without informing them of the potential risks or getting prior consent. The FDA is unmotivated to initiate a query unless they are alerted that a problem exists. This could take years and put millions of lives at risk. Such appears to be true of cancer plaguing users of Zantac.

Over 500 individual Zantac heartburn and antacid users have filed lawsuits against Sanofi for failing to warn them of the cancer risk taking the drug allegedly represents. Experts expect tens of thousands of more Zantac cancer victims to file in the months to come. It took a petition delivered from online prescription drug testing pharmacy Valisure to get the FDA to recall all ranitidine tablets. This despite people for years complaining that they were taking Zantac and developing gastrointestinal cancer. Valisure tested Zantac and found the presence of NDMA, a carcinogen that is banned in the US but was once given to laboratory animals to induce tumors. Valisure found elevated levels of NDMA in all of the Zantac tablets they tested. Some Zantac tested contained thousands of times more NDMA than the 96Ngs per tablet the FDA had set as a threshold for patient safety.

The most recently published scientific study queried the FDA's Adverse Events Reporting System (FAERS) to see if people who took H2 Antagonist medicines like ranitidine (Zantac), had a greater likelihood of developing certain types of cancer than those who took protein pump inhibitor (PPI) drugs like Prilosec and others. PPI heartburn drugs have been tested and found to be uncontaminated with NDMA, although some are starting to link them with developing type-2 diabetes, however, that is a topic for another article. To summarize the latest report, individuals that took ranitidine had a higher likelihood to develop certain gastrointestinal cancer. NewYorkLegalExaminer wrote, "The scientists found elevated incidences of cancers such as esophageal, stomach, colorectal, liver, and pancreatic among those taking Zantac (ranitidine). The researchers concluded that the study results, in addition to other research, "support the hypothesis that NDMA-contaminated ranitidine increases the risk of cancer."

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.